PURPOSE: To describe temporal trends in Pseudomonas aeruginosa resistance to moxifloxacin in keratitis isolates from South India. METHODS: The Steroids for Corneal Ulcers Trial (SCUT) was a randomized, double-masked, placebo-controlled trial assessing outcomes in patients with culture positive bacterial corneal ulcers randomized to receive prednisolone phosphate or placebo. All patients received moxifloxacin, and susceptibility to moxifloxacin was measured at baseline using Etest. We investigated trends in moxifloxacin susceptibility of P. aeruginosa during 2007, 2008, and 2009 isolated in SCUT in South India. RESULTS:There were 89 P. aeruginosa isolates during 2007, 2008, and 2009 in SCUT that were eligible for this study. There was an increase in the proportion of resistant isolates from 19% in 2007 to 52% in 2009 (p = 0.02, χ(2) test for trend). Logistic regression showed that there was a 2-fold increase in odds of resistance per 1 year increase during the study period (odds ratio 2.16, 95% confidence interval 1.09-4.26, p = 0.027). CONCLUSIONS: We found a sharp increase in the proportion of isolates that were resistant to moxifloxacin from 2007 to 2009. Further work needs to be done to characterize the nature of this increase.
RCT Entities:
PURPOSE: To describe temporal trends in Pseudomonas aeruginosa resistance to moxifloxacin in keratitis isolates from South India. METHODS: The Steroids for Corneal Ulcers Trial (SCUT) was a randomized, double-masked, placebo-controlled trial assessing outcomes in patients with culture positive bacterial corneal ulcers randomized to receive prednisolone phosphate or placebo. All patients received moxifloxacin, and susceptibility to moxifloxacin was measured at baseline using Etest. We investigated trends in moxifloxacin susceptibility of P. aeruginosa during 2007, 2008, and 2009 isolated in SCUT in South India. RESULTS: There were 89 P. aeruginosa isolates during 2007, 2008, and 2009 in SCUT that were eligible for this study. There was an increase in the proportion of resistant isolates from 19% in 2007 to 52% in 2009 (p = 0.02, χ(2) test for trend). Logistic regression showed that there was a 2-fold increase in odds of resistance per 1 year increase during the study period (odds ratio 2.16, 95% confidence interval 1.09-4.26, p = 0.027). CONCLUSIONS: We found a sharp increase in the proportion of isolates that were resistant to moxifloxacin from 2007 to 2009. Further work needs to be done to characterize the nature of this increase.
Authors: Prajna Lalitha; Muthiah Srinivasan; P Manikandan; M Jayahar Bharathi; Revathi Rajaraman; Meenakshi Ravindran; Vicky Cevallos; Catherine E Oldenburg; Kathryn J Ray; Christine M Toutain-Kidd; David V Glidden; Michael E Zegans; Stephen D McLeod; Nisha R Acharya; Thomas M Lietman Journal: Clin Infect Dis Date: 2012-03-23 Impact factor: 9.079
Authors: Hugo Y Hsu; Randall Nacke; Jonathan C Song; Sonia H Yoo; Eduardo C Alfonso; Heidi A Israel Journal: Eye Contact Lens Date: 2010-07 Impact factor: 2.018
Authors: Michaelle Chojnacki; Alesa Philbrick; Benjamin Wucher; Jordan N Reed; Andrew Tomaras; Paul M Dunman; Rachel A F Wozniak Journal: Antimicrob Agents Chemother Date: 2018-12-21 Impact factor: 5.191
Authors: Sumayya Ahmad; Michelle Lopez; Marwan Attala; Anat Galor; Natalie A Stanciu; Darlene Miller; Leejee Suh; Thomas Albini; Victor L Perez; Carol L Karp; Janet L Davis; Eduardo Alfonso; Richard K Forster; Guillermo Amescua Journal: Ocul Immunol Inflamm Date: 2017-10-17 Impact factor: 3.070
Authors: Rose Herbert; Mary Caddick; Tobi Somerville; Keri McLean; Shakeel Herwitker; Timothy Neal; Gabriela Czanner; Stephen Tuft; Stephen B Kaye Journal: BMJ Open Ophthalmol Date: 2022-07